South Africa Receives Lenacapavir for HIV

South Africa has received its first batch of 37,920 doses of Lenacapavir, a six-monthly injectable HIV prevention medicine. This marks a significant advancement in the country's integrated HIV prevention strategy, aiming to reduce new infections and end AIDS as a public health threat by 2030. The South Africa===Department of Health (South Africa) announced the arrival, with Minister of Health Aaron Motsoaledi expressing enthusiasm. The South Africa===South African Health Products Regulatory Authority officially registered Lenacapavir (branded as Sunlenca) on October 27, 2025, making South Africa the first country in Africa to authorize this twice-yearly injection for HIV prevention. An official launch and phased implementation plan will be announced in the coming weeks, led by the President. Lenacapavir is considered a groundbreaking advance, offering improved adherence, especially among vulnerable groups.